Skip to main
FDMT
FDMT logo

FDMT Stock Forecast & Price Target

FDMT Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 15%
Sell 8%
Strong Sell 0%

Bulls say

4D Molecular Therapeutics Inc has demonstrated notable efficacy in its ophthalmology product candidates, specifically with positive clinical trial results showing significant gains in Best-Corrected Visual Acuity (BCVA) and reductions in injection burden among recently diagnosed patients. The company boasts a strong financial position with an extended cash runway of $505 million projected to last into 2028, which is expected to facilitate the advancement of pivotal studies. Furthermore, 4D Molecular Therapeutics is strategically aligning its research focus to target high-need areas within ophthalmology and cystic fibrosis, indicating a commitment to sustainable growth and enhanced shareholder value through innovative gene therapy solutions.

Bears say

4D Molecular Therapeutics exhibits a negative outlook due to significant net losses, amounting to $161 million for 2024, which reflects an unsustainable operational model given its non-revenue generating status. Furthermore, the company faces potential downward revisions to its valuation if early-stage trial results are not replicated in later phases, or if new safety concerns arise within its product pipeline. Compounding these issues, 4D's limited manufacturing capacity and complexities inherent in AAV-based gene therapy could lead to delays in product development and commercialization, adding further uncertainty to its financial projections.

FDMT has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 4D Molecular Therapeutics (FDMT) Forecast

Analysts have given FDMT a Buy based on their latest research and market trends.

According to 13 analysts, FDMT has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

4D Molecular Therapeutics (FDMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.